The global uveitis treatment market size is expected to reach USD 4.10 billion by 2030, according to a new report by Grand View Research, Inc. It is projected to register a CAGR of 9.1% from 2024 to 2030. Rising prevalence of the condition is anticipated to drive the growth. For instance, according to The Ocular Immunology and Uveitis Foundation, around 43,000 new eye inflammation cases are being diagnosed each year in U.S.
Eye inflammation is also very prevalent among children. However, majority of the affected population ranges from 20 to 50 years of age. Growing geriatric population is also an important factor driving the growth of the market. Rise in number of R&D activities aiming at new drug development is another attribute increasing the demand for these treatments.
For instance, ADX-102 Ophthalmic Solution, by Aldeyra Therapeutics, Inc. is in Phase 2 clinical trial for the treatment of noninfectious anterior uveitis. The National Eye Institute is also engaged in conducting and supporting various research studies in this field. Increasing prevalence of infectious diseases is another contributing factor to the market growth. Infectious uveitis surrounds a significant array of potential pathogens, which is likely to pose immense threat to the people affected.
Request a free sample copy or view report summary: Uveitis Treatment Market Report
Corticosteroids led the market in 2023 owing to its wide application for treating noninfectious uveitis as well as availability of varied corticosteroids drugs
Monoclonal antibodies are expected to exhibit lucrative CAGR over the forecast period due to rising development of novel biologic drugs
Anterior held the largest market share in 2023 owing to growing prevalence and tendency of recurrence of anterior uveitis
Posterior is anticipated to showcase lucrative growth over the forecast period owing to rise in the number of R&D and clinical trials undergoing for the treatment posterior uveitis
Noninfectious segment held significant revenue share in 2023 owing to the wide array of treatment methods coupled with rising cases of the condition
Infectious segment is gaining traction in the uveitis treatment market owing to rising prevalence of infectious diseases
North America held the largest revenue share in 2023 owing to increasing prevalence of noninfectious uveitis as well as rising healthcare expenditure in this region
Asia Pacific is anticipated to exhibit lucrative CAGR over the forecast period due to the rising number of infectious diseases in the developing countries
Grand View Research has segmented the global uveitis treatment market report based on treatment, disease, cause, distribution channel, and region:
Uveitis Treatment Treatment Outlook (Revenue, USD Million, 2018 - 2030)
Corticosteroids
Immunosuppressant
Monoclonal Antibodies
Cycloplegic Agents
Antibiotics
Antivirals
Antifungal
Analgesics
Uveitis Treatment Disease Outlook (Revenue, USD Million, 2018 - 2030)
Anterior Uveitis
Posterior Uveitis
Intermediate Uveitis
Panuveitis
Uveitis Treatment Cause Outlook (Revenue, USD Million, 2018 - 2030)
Infectious
Non-infectious
Uveitis Treatment Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
Uveitis Treatment Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Mexico
Canada
Europe
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
South Korea
Thailand
Australia
Latin America
Brazil
Argentina
MEA
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players in Uveitis Treatment Market
AbbVie Inc.
Santen Pharmaceutical Co., Ltd.
Bausch Health Companies Inc.
Regeneron Pharmaceuticals Inc.
EyePoint Pharmaceuticals, Inc.
Novartis AG
Ocular Therapeutix, Inc.
Ophthotech Corporation
Pfizer Inc.
"The quality of research they have done for us has been excellent..."